EHA 2022 | Molecular pathogenesis and immune dysregulation in MDS
In this video, Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China talks on the molecular pathogenesis of myelodysplastic syndromes (MDS). Specifically, Dr Gill discusses epigenetic changes, splicing factor mutations, and histone modification gene mutations, as well as the interplay between these genetic factors and the dysregulated immune profile of MDS patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Oncology – honoraria, consultancies; Celgene/bms – research grant, honoraria, consultancies; PharmaEssentia – research grant; Abbvie – honoraria, consultancies; Takeda – honoraria; Pfizer Oncology – honoraria, consultant
